Exelixis Q1 revenue up 15% to $408.8M, but GAAP EPS falls to $0.12 on higher R&D spend

EXELIXIS, INC.

2023-Q1 EPS reported $0.12 revenue$408,788,000

Total revenues $408.8M (+15% YoY); Cabozantinib franchise net product revenues $363.4M (+17% YoY).
GAAP net income $40.0M ($0.12 diluted EPS) vs $68.6M ($0.21) YoY; non-GAAP diluted EPS $0.16 vs $0.26.
R&D expense rose to $234.2M from $156.7M YoY, driven by license costs and pipeline manufacturing.
Announced $550M share repurchase program to be executed by end of 2023; reaffirms long-term confidence.
Pipeline advances: STELLAR-303 and -304 Phase 3 trials for zanzalintinib, XB002 Phase 1 dose escalation ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXELIXIS, INC. reported First Quarter 2023 results: revenue $408.8 million, EPS GAAP Diluted EPS of $0.12.

Period: First Quarter 2023
Revenue: $408.8 million
EPS: GAAP Diluted EPS of $0.12
Result: reported results

Exact text from the filing

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -

View on SEC.gov

Browse all earnings releases →

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.